# Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

Source: https://onco.cc/trials/nct05748145/  
OnCo record `nct05748145` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Oncology Institute of Southern Switzerland, now recruiting.

## Summary

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001 is a phase 2, interventional study registered as NCT05748145 by Oncology Institute of Southern Switzerland, with a registry enrolment figure of 40 participants, started 2023-09-11 and due to reach its primary completion in 2026-12-31. Interventions recorded: Metronidazole Oral. Conditions listed: Colorectal Cancer. Primary outcome: Impact of metronidazole on F.n. loads in CRC tissues.. Colorectal eligibility wording from the registry: "* Untreated, primary colorectal adenocarcinoma (\> 15 cm from the anal verge)". Sites: Switzerland. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05748145
- Phase: 2
- Setting: Preoperative Treatment With Metronidazole to Evaluate the Efficacy in Reducing Fusobacterium Nucleatum Tumor Colonization in Patients With Colorectal Cancer (CRC): a Proof-of-concept Trial
- Sponsor: Oncology Institute of Southern Switzerland
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT05748145: https://clinicaltrials.gov/study/NCT05748145

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05748145.json